Penumbra Inc (PEN) · Oct 29, 2026 · Earnings
Beat — Revenue $410.1M vs ~$401.4M consensus; diluted EPS $1.07 vs ~$1.00 GAAP consensus
Penumbra earnings beat Q3 revenue and GAAP EPS consensus, with thrombectomy growth accelerating even as taxes and acquisition costs pressured profit.
Penumbra is still expanding its clot-removal franchise across stroke, venous thromboembolism and other vascular conditions, but it is operating under a pending Boston Scientific acquisition that has already changed how management communicates. The merger was announced earlier in 2026, making this effectively one of the company’s last standalone operating updates.
The quarter beat the published bar on both revenue and GAAP EPS. Revenue reached $410.1 million, ahead of the roughly $401.4 million consensus, while diluted GAAP EPS was $1.07 versus an approximately $1.00 consensus estimate. That makes this a genuine earnings beat, not merely a year-over-year growth story.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue ($M) (Income Statement) | $410.1M (+15.6%) | $354.7M | ~$401.4M |
| Diluted EPS (Income Statement) | $1.07 | $1.17 | ~$1.00 |
| Thrombectomy revenue ($M) (Revenue by product) | $279.2M (+18.1%) | $236.4M | |
| Net income ($M) (Income Statement) | $42.3M (-7.8%) | $45.9M |
The core growth engine remains healthy, especially in U.S. venous procedures. Global thrombectomy revenue rose 18.1%, with U.S. VTE revenue up 26.0%, showing that the quarter’s beat came from the strategic product areas Boston Scientific is acquiring rather than from a one-off balance-sheet item. 〔0〕
Profit growth was less impressive than the top line. Operating income was essentially flat for the first nine months despite 15.4% revenue growth, while third-quarter net income fell because the tax provision more than doubled year over year. SG&A also rose 20.9%, including $7.1 million of acquisition-related costs, so the headline EPS beat comes with some pressure beneath the surface.
The acquisition makes the outlook deliberately harder to read. Penumbra is withholding full-year 2026 guidance and skipping the earnings call because of the pending transaction, so investors get a solid operating snapshot but no fresh management view on the year or on the integration path. That is expected given the deal, not a new deterioration in the business. 〔1〕
Bottom line: This was a modestly better-than-expected operating quarter, led by strong thrombectomy and U.S. VTE demand. The beat matters, but the pending sale and weaker net-income conversion limit how much new standalone information the filing adds beyond confirming that the underlying franchise remains on track.
Boston Scientific acquisition closing
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!